• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期和中期肝细胞癌患者行肝切除术后的肿瘤负担:一项关于临床和肿瘤学结局的回顾性多中心研究。

Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes.

机构信息

Department of Visceral Surgery, University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland.

Department of Liver Surgery, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

HPB (Oxford). 2023 Jul;25(7):836-844. doi: 10.1016/j.hpb.2023.04.001. Epub 2023 Apr 9.

DOI:10.1016/j.hpb.2023.04.001
PMID:37098458
Abstract

BACKGROUND

According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediate-stage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassification tumour burden score (TBS).

METHODS

All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages.

RESULTS

Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343).

CONCLUSIONS

Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.

摘要

背景

根据巴塞罗那临床肝癌(BCLC)分期系统,肝切除术(LR)推荐用于早期(BCLC-A)肝细胞癌(HCC),但不适用于中期(BCLC-B)。本研究旨在使用肿瘤负荷评分(TBS)评估这些患者接受 LR 的结果。

方法

纳入了 2010 年 1 月至 2020 年 12 月在 4 家三级转诊中心接受 LR 治疗的所有连续 BCLC-A 和 BCLC-B HCC 患者。评估了 TBS 和 BCLC 分期与临床结果和总生存期(OS)的关系。

结果

在纳入的 612 例患者中,562 例被分类为 BCLC-A,50 例被分类为 BCLC-B。整体术后并发症发生率(56.0%比 41.5%,p=0.053)和死亡率(0 比 1.6%,p=1.000)在 BCLC-A 和 BCLC-B 患者之间相似。BCLC A/低 TBS 的 OS 明显高于 BCLC B/低 TBS(p=0.009),而中高 TBS 患者的 OS 相似,与 BCLC 分期无关(分别为 p=0.103 和 p=0.343)。

结论

中高 TBS 患者无论 BCLC A 或 B 期,其 OS 和DFS 相当,术后发病率相当。这些结果强调了需要改进 BCLC 分期系统,并且可以根据肿瘤负荷考虑将 LR 用于选定的中期(BCLC-B)。

相似文献

1
Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes.早期和中期肝细胞癌患者行肝切除术后的肿瘤负担:一项关于临床和肿瘤学结局的回顾性多中心研究。
HPB (Oxford). 2023 Jul;25(7):836-844. doi: 10.1016/j.hpb.2023.04.001. Epub 2023 Apr 9.
2
Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.肝细胞癌肿瘤负荷评分用于分层切除术后的预后。
Br J Surg. 2020 Jun;107(7):854-864. doi: 10.1002/bjs.11464. Epub 2020 Feb 14.
3
Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages.影像学肿瘤负担评分可用于分层巴塞罗那临床肝癌分期不同的肝癌切除术患者的总生存。
Langenbecks Arch Surg. 2023 May 1;408(1):169. doi: 10.1007/s00423-023-02869-6.
4
Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.BCLC-B 期肝细胞癌肝切除术的手术和肿瘤学结果:474 例连续病例的回顾性多中心分析。
Updates Surg. 2019 Jun;71(2):285-293. doi: 10.1007/s13304-019-00649-w. Epub 2019 Apr 2.
5
Tumor burden score as a prognostic factor in patients with intermediate and locally advanced hepatocellular carcinoma undergoing liver resection: an attempt to extend resectability criteria.肿瘤负担评分作为中危和局部进展期肝细胞癌行肝切除术患者的预后因素:扩大可切除性标准的尝试。
HPB (Oxford). 2024 Sep;26(9):1180-1189. doi: 10.1016/j.hpb.2024.05.021. Epub 2024 May 31.
6
Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines.利用机器学习对接受 BCLC-0、A 和 B 期肝细胞癌切除术的患者进行术前和术后评估:BCLC 指南以外的切除术的意义。
Ann Surg Oncol. 2020 Mar;27(3):866-874. doi: 10.1245/s10434-019-08025-z. Epub 2019 Nov 6.
7
Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number.肿瘤大小和数量之和决定的中期肝细胞癌的术后结果和复发模式。
World J Gastroenterol. 2022 Nov 28;28(44):6271-6281. doi: 10.3748/wjg.v28.i44.6271.
8
Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy.包裹肿瘤簇的血管(VETC)对肝癌切除术后不同分期患者预后的影响。
Dig Liver Dis. 2023 Sep;55(9):1288-1294. doi: 10.1016/j.dld.2023.03.008. Epub 2023 Apr 9.
9
Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.肝切除术为选定的中期(BCLC-B)肝细胞癌患者带来生存获益。
Cancer Res Treat. 2019 Jan;51(1):65-72. doi: 10.4143/crt.2018.038. Epub 2018 Feb 26.
10
Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma.肿瘤负担评分和血清甲胎蛋白亚类可细分中期肝细胞癌。
J Gastrointest Surg. 2022 Dec;26(12):2512-2521. doi: 10.1007/s11605-022-05469-9. Epub 2022 Sep 28.

引用本文的文献

1
Identification of candidates with hepatocellular carcinoma to receive TACE combined with MWA by assessing tumor burden and radiologic features.通过评估肿瘤负荷和影像学特征来识别肝细胞癌患者接受经动脉化疗栓塞(TACE)联合微波消融(MWA)治疗的候选者。
Ther Adv Med Oncol. 2025 Mar 15;17:17588359251324052. doi: 10.1177/17588359251324052. eCollection 2025.
2
A deep learning model for personalized intra-arterial therapy planning in unresectable hepatocellular carcinoma: a multicenter retrospective study.用于不可切除肝细胞癌个性化动脉内治疗规划的深度学习模型:一项多中心回顾性研究
EClinicalMedicine. 2024 Sep 5;75:102808. doi: 10.1016/j.eclinm.2024.102808. eCollection 2024 Sep.
3
Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma.
探讨肝切除术作为多结节BCLC-A期肝细胞癌一线治疗选择的作用。
J Liver Cancer. 2024 Sep;24(2):126-128. doi: 10.17998/jlc.2024.08.08. Epub 2024 Aug 16.